Clinical Trials Logo

Filter by:
NCT ID: NCT03214380 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

PRONTO-T2D
Start date: July 14, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

NCT ID: NCT03214367 Recruiting - Clinical trials for Type 1 Diabetes Mellitus

A Study of LY900014 in Participants With Type 1 Diabetes

PRONTO-T1D
Start date: July 17, 2017
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

NCT ID: NCT03213457 Recruiting - Endometriosis Clinical Trials

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Start date: July 7, 2017
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects. This is a study that assess the safety and efficacy of elagolix in combination with concomitant hormonal add-back therapy in premenopausal 18 to 49 year old women with moderate to severe endometriosis-associated pain.

NCT ID: NCT03212521 Recruiting - Clinical trials for Hepatitis C Virus (HCV)

A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment

Start date: August 7, 2017
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.

NCT ID: NCT03188185 Recruiting - Clinical trials for Major Depressive Disorder

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

NCT ID: NCT03185013 Recruiting - Cervical Dysplasia Clinical Trials

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

REVEAL 1
Start date: June 13, 2017
Phase: Phase 3
Study type: Interventional

HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16 and/or HPV-18.

NCT ID: NCT03180684 Recruiting - Neoplasms, Vulvar Clinical Trials

VGX-3100 Followed by Electroporation Alone or in Combination With Imiquimod for the Treatment of Human Papilloma Virus HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva

Start date: June 26, 2017
Phase: Phase 2
Study type: Interventional

This phase 2, randomized, open label study will investigate the efficacy of VGX-3100 followed by electroporation (EP) with CELLECTRA® 2000 alone or in combination with imiquimod in participants with human papillomavirus (HPV)-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the vulva.

NCT ID: NCT03159078 Recruiting - Critical Illness Clinical Trials

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

MUSEUM
Start date: May 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against MDR gram negative infections. The investigators intend to evaluate if this synergistic drug regimen correlates with improved outcomes against gram-negative infections in critically ill patients including: better clinical resolution, reduced length of stay at hospital, reduced length of stay at the intensive care unit, and less recurrence of infection.

NCT ID: NCT03158233 Recruiting - Zika Virus Disease Clinical Trials

Zika Case Definition and Surveillance Study

Start date: April 28, 2017
Phase: N/A
Study type: Observational

This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the study cohort.

NCT ID: NCT03142841 Not yet recruiting - Depression Clinical Trials

Spanish Intervention for Caregivers of Veterans With Stroke

RESCUE Espa ol
Start date: July 2017
Phase: N/A
Study type: Interventional

This research study will test a problem-solving intervention for Spanish-speaking stroke caregivers that will be delivered over the telephone and online via the previously developed and nationally available Spanish version of the RESCUE website. The investigators will adapt their previously pilot-tested problem-solving intervention and make it culturally-relevant for Hispanic caregivers. The investigators' main goal is to test the efficacy of a brief, telephone and online problem-solving intervention. The objectives are: 1) reduce caregiver burden and depression, 2) improve caregivers' problem-solving abilities, self-efficacy, and quality of life, 3) improve Veterans' functional abilities and determine the intervention's impact on Veterans' healthcare utilization, 4) determine budgetary impact, and 5) determine caregivers' perceptions of the intervention.